Đang chuẩn bị liên kết để tải về tài liệu:
MammaPrint guides treatment decisions in breast Cancer: Results of the IMPACt tria
Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Increased usage of genomic risk assessment assays suggests increased reliance on data provided by these assays to guide therapy decisions. The current study aimed to assess the change in treatment decision and physician confidence based on the 70-gene risk of recurrence signature (70-GS, MammaPrint) and the 80-gene molecular subtype signature (80-GS, BluePrint) in early stage breast cancer patients. | MammaPrint guides treatment decisions in breast Cancer Results of the IMPACt tria